In Vitro Effects of the Novel Platelet αIIbβ3 Receptor Antagonist RUC-4 on the Verifynow Assays: Potential for Point-of-Care Monitoring of RUC-4 Therapy
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-124548
Abstract: Introduction: RUC-4 is a novel platelet integrin αIIbβ3 antagonist specifically designed for first point-of-medical contact (ambulance or ER) treatment of patients with ST segment elevation myocardial infarction in combination with aspirin. Ongoing Phase 1 studies… read more here.
Keywords: isotrap; blood; adp pge1; pge1 channel ... See more keywords